| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Moleculin Biotech Inc. | Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE) | Acute Myeloid Leukemia (AML) | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| Moleculin Biotech Inc. | WP1066 | Pediatric Recurrent Malignant Brain Tumors | Phase 2 | Trial Planned | Oral | Oncology |
| Moleculin Biotech Inc. | WP1066 | Pediatric Recurrent Malignant Brain Tumors | Phase 2 | Trial Planned | Oral | Oncology |
| Moleculin Biotech Inc. | WP1066 | Glioblastoma (NU 21C06) | Phase 2 | Ongoing | Oral | Oncology |
| Moleculin Biotech Inc. | WP1066 | Recurrent Malignant Glioma | Phase 2 | Ongoing | Oral | Oncology |
| Monopar Therapeutics Inc. | ALXN1840 (WTX101) - (FoCus) | Wilson disease | Phase 3 | Data Released | Oral | Genetic Disorder |
| Monopar Therapeutics Inc. | ALXN1840 (WTX101) - (FoCus) | Wilson disease | Phase 3 | Data Released | Oral | Genetic Disorder |
| Monopar Therapeutics Inc. | Validive - (VOICE) | Oral mucositis | Phase 2/3 | Trial Discontinued | Buccal | Wound Care |